TXG News and Press, 10x Genomics Inc. From 01/19/23

Summary Bruker offers a range of advantages over peers: profitability, value, growth, and more. As such, the company is well-positioned to provide strong returns in the future. This article will address recent developments, highlight the advantages, and discuss the opportunity. ...

(All amounts expressed in U.S. Dollars unless otherwise stated) TORONTO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Torex Gold Resources Inc. (the “Company” or “Torex”) (TSX: TXG) provides 2023 operational guidance as well as a 5-year production outlook for the Morelos Comp...

TORONTO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Torex Gold Resources Inc. (the “Company” or “Torex”) (TSX: TXG) reports record annual gold production of 474,035 ounces in 2022 following fourth quarter production of 116,196 ounces. Full year gold production surpassed the upp...

10x Genomics to Present at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire PLEASANTON, Calif. , Dec. 28, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today annou...

Summary 10x Genomics is targeting larger addressable market opportunities over the mid to long term. The accelerated Xenium launch will bolster the growth potential but may be insufficient to plug a looming shortfall next year. While cost cuts will help, it remains unclear if they w...

10x Genomics Commercially Launches Xenium Platform for In Situ Analysis PR Newswire Began global shipments of Xenium Analyzer, the highest throughput instrument for subcellular In Situ profiling PLEASANTON, Calif. , Dec. 8, 2022 /PRNewswire/ -- 10x Ge...

10x Genomics Launches BEAM to Improve and Streamline Antibody and T-Cell Receptor Discovery PR Newswire Barcode Enabled Antigen Mapping (BEAM) screens multiple antigens against thousands of B- or T-cells to identify novel and rare antigen-specific repertoires ...

10x Genomics ( NASDAQ: TXG ) stock rose ~17% on Thursday after Q3 results beat estimates and the company maintained its FY22 revenue outlook. Net loss per share widened to -$0.37, compared to -0.15 in Q3 2021. Meanwhile, revenue grew +4.6% Y/Y to $131.07M....

10x Genomics, Inc. (TXG) Q3 2022 Earnings Conference Call November 02, 2022 04:30 PM ET Company Participants Cassie Corneau - Head, Investor Relations & Strategic Finance Serge Saxonov - Chief Executive Officer & Co-Founder Justin McAnear - Chief Financia...

10x Genomics press release ( NASDAQ: TXG ): Q3 GAAP EPS of -$0.37 beats by $0.11 . Revenue of $131.07M (+4.6% Y/Y) beats by $1.94M . Cash and cash equivalents and marketable securities were $452.4 million as of September 30, 2022. 2022 Guidance: ...